Rik S.
- Country
- Belgium
- Department
- Hematology
Research Overview
- Phase III Evaluation of Belantamab Mafodotin, Bortezomib, and Dexamethasone Versus Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
- Phase 3 Randomized Open-Label Trial of Epcoritamab Versus Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Phase II Multicenter Randomized Trial of WT1 mRNA-Electroporated Dendritic Cell Vaccination for Relapse Prevention in Adult Acute Myeloid Leukemia
Data & Insights
Has run more than one trial at 48 of 180 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in hematological malignancies, with particular focus on allogeneic hematopoietic cell transplantation.
- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndromes (MDS)
- Chronic Myeloid Leukemia (CML)
- Myeloproliferative Disorders (MPD)
Areas of expertise include innovative conditioning regimens for transplantation and treatment of complex blood disorders.
Lymphoid Malignancies
The investigator focuses on treating various lymphoid cancers through advanced therapeutic approaches.
- Acute Lymphoblastic Leukemia (ALL)
- Multiple Myeloma
- Chronic Lymphocytic Leukemia (CLL)
- Non-Hodgkin's Lymphoma
- Hodgkin's Disease
Particular interest in chemosensitive disease management and response to checkpoint inhibitors.
Transplant Medicine
The investigator studies advanced conditioning regimens for transplantation procedures.
- HLA-matched donor transplantation
- Reduced-intensity conditioning
- Post-transplant cyclophosphamide
- Anti-thymocyte globulin protocols
Focus on developing optimal conditioning strategies for improved transplant outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.